Digest Network Come funziona
Network
/
Società
Su
Non verificato

Summit Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

41 comunicati stampa

Guarda tutti i comunicati
13/09/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Eventi
Industria
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
Fonte
Summit Therapeutics
Emittente
Business Wire
1.00
0
02/09/2026
Industria
Scienza
Biotecnologia
Medicina - Varie
Sanità
Farmaceutica
Salute
Oncologia
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China
Fonte
Summit Therapeutics
Emittente
Business Wire
1.00
0
25/08/2026
Analisi di mercato
Industria
Scienza
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Oncologia
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
Fonte
Summit Therapeutics
Emittente
Business Wire
1.00
0
25/08/2026
Industria
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
Fonte
Summit Therapeutics
Emittente
Business Wire
1.00
0
12/08/2026
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
Fonte
Summit Therapeutics
Emittente
Business Wire
1.00
0
05/08/2026
Analisi di mercato
Industria
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
Fonte
Summit Therapeutics
Emittente
Business Wire
1.00
0
23/07/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Sanità
Farmaceutica
Salute
Oncologia
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
Fonte
Summit Therapeutics
Emittente
Business Wire
1.00
0
22/07/2026
Mercato del lavoro
Scienza
Igiene alimentare
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Oncologia
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
Fonte
Summit Therapeutics
Emittente
Business Wire
1.00
0
22/07/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Sanità
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
Fonte
Summit Therapeutics
Emittente
Business Wire
1.00
0
16/07/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
Fonte
Summit Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0